Journal of Biomolecular Screening
| Robert M. Campbell, PhD | Twentyeight-seven Therapeutics, Watertown, MA |
Advancing Life Sciences R&D! In January 2017, JBS will become SLAS Discovery.
JBS reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.
The Journal of Biomolecular Screening (JBS) is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. JBS publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. JBS is an official journal of the Society for Laboratory Automation and Screening (SLAS).
The journal emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/ optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.
This publication will be of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.
This journal is a member of the Committee on Publication Ethics (COPE)